Sanofi SA (NASDAQ:SNY) on Thursday reported second-quarter sales of $13.482 billion (11.597 billion euros), beating the consensus of $12.65 billion.
Sales increased 16% year over year, up 17.8% in constant currency.
Dupixent Drives Growth While Vaccines Sales Decline Dupixent sales increased by 37.6% to 5.154 billion euros, above 5 billion euros per quarter for the first time.
Global sales continued to be driven by strong volume growth across approved indications, and Dupixent retained a leading market position across its disease areas.
Vaccines sales were 1.15 billion euros and decreased by 4.7%, mainly driven by lower sales of influenza and meningitis, travel, and endemic vaccines.
